We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Bristol Myers Squibb (BMY) Com Stk USD 0.10 (CDI)

Sell:$57.23 Buy:$57.24 Change: $0.46 (0.82%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$57.23
Buy:$57.24
Change: $0.46 (0.82%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$57.23
Buy:$57.24
Change: $0.46 (0.82%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.

Contact details

Address:
Route 206 And Province Line Road
PRINCETON
08543
United States
Telephone:
+1 (609) 2524621
Website:
https://www.bms.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BMY
ISIN:
US1101221083
Market cap:
$115.28 billion
Shares in issue:
2.03 billion
Sector:
Pharmaceuticals
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Christopher Boerner
    Chairman of the Board, Chief Executive Officer, Chief Operating Officer
  • David Elkins
    Executive Vice President, Chief Financial Officer, Member of the Leadership Team
  • Lynelle Hoch
    President, Cell Therapy Organization, Member of the Leadership Team
  • Amanda Poole
    Chief Human Resource Officer, Executive Vice President, Member of the Leadership Team
  • Greg Meyers
    Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
  • Sandra Leung
    Executive Vice President, General Counsel, Member of the Leadership Team
  • Cari Gallman
    Executive Vice President, Corporate Affairs, Member of the Leadership Team
  • Samit Hirawat
    Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
  • Adam Lenkowsky
    Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
  • Robert Plenge
    Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.